Clinical Observation of Rutongshu Oral Liquid in Treating Hyperplasia of Mammary Glands with Liver Depression and Qi Stagnation Type

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2026000881

Enrollment

Unknown

Registered

2026-04-03

Start date

2024-06-01

Completion date

Unknown

Last updated

2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperplasia of mammary glands

Interventions

Control group:Tamoxifen citrate Tablets

Research team:Rutongshu Oral Liquid

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1: Patients with breast disease of liver-stagnation and qi-stagnation type meeting the diagnostic criteria; 2: Course of disease >3 months; 3: Women aged between 20 and 45; 4: Those who voluntarily agree to sign the informed consent for.

Exclusion criteria

Exclusion criteria: 1: Patients with other breast diseases such as mastitis, intraductal papilloma, and breast cancer; 2: Course of disease <3 months; 3: Women under 20 years old or over 45 years old; 4: Suffering from acute and chronic diseases of the heart, brain, kidneys and liver, as well as somatic organic disorders; 5: Combine with severe mental disorders; 6: Those unable to comply with treatment; 7: Pregnant and breastfeeding women; 8: Patients with allergic constitution.

Design outcomes

Primary

Measure	Time frame
TCM syndrome points;Indicators of sex hormone levels;Evaluation of breast hyperplasia;	—

Countries

China

Contacts

Public ContactZheng Fan

The Seventh Affiliated Hospital of Anhui University of Traditional Chinese Medicine

13615679696@139.com13615679696

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026